Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

69.85 -0.22 (-0.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
67 68 Next >
NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?
The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs. 
Via InvestorPlace
Markets suddenly price Eli Lilly stock for a breakout on earnings
The healthcare sector could see a sudden inflow of investment dollars, and Eli Lilly quickly becomes a favorite name in the space as markets and analysts bid up 
Via MarketBeat
Topics Bonds Economy
History Says the Nasdaq Will Keep Soaring in 2024. Here's the Surprising Megacap Stock Wall Street Thinks Will Be the Biggest Winner.
Hint: It's not Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, or Tesla. 
Via The Motley Fool
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Check Out What Whales Are Doing With AZN
Via Benzinga
Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry
Via Benzinga
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market. 
Via Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
A reasonably modest amount of money can go a long way when it's put to work in industry-leading businesses. 
Via The Motley Fool
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
Pfizer’s earnings growth trade at a deep discount, suddenly a buy
The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite 
Via MarketBeat
Topics Economy
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors
From AstraZeneca
Via Business Wire
3 Magnificent Stocks to Buy and Hold Forever
Many investors will want to consider owning these stocks for a long time. 
Via The Motley Fool
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
From AstraZeneca
Via Business Wire
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech... 
Via Talk Markets
AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study
Explore results from AstraZeneca's EMERALD-1 Phase 3 trial on Imfinzi for unresectable hepatocellular carcinoma. Statistically significant improvement in progression-free survival with Imfinzi plus... 
Via Benzinga
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
From AstraZeneca
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold
Be sure to sell these meme stocks as they represent fundamentally weak businesses that will continue to erode in value. 
Via InvestorPlace
MarketBeat Week in Review – 1/8 - 1/12
Stocks drifted lower as the latest inflation numbers are dampening expectations for a rate cut; here are some of our top stories for your long weekend 
Via MarketBeat
Topics ETFs Economy
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed... 
Via Benzinga
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution
Via Investor Brand Network
Topics Intellectual Property
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst. 
Via Investor's Business Daily
Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense
Join the fight against Nipah virus! Oxford Vaccine Group launches groundbreaking ChAdOx1 NipahB vaccine trial, targeting the deadly virus. 51 participants aged 18-55. Funded by CEPI. Help combat Nipah... 
Via Benzinga
AstraZeneca: Rebound in 2024 with double-digit earnings growth
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
Via Investor Brand Network
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-fueled Nasdaq Composite is 9% below its record high, meaning amazing deals are still hiding in plain sight. 
Via The Motley Fool
Topics Stocks
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.